{
    "RADCURE-0971": {
        "question": "Age: 63.6, Sex: Male, ECOG PS: ECOG 1, Smoking PY: 45, Smoking Status: Ex-smoker, Ds Site: Larynx, Subsite: Supraglottis, T: T2, N: N0, M : M0, Stage: II, Path: Squamous Cell Carcinoma, HPV: none, Tx Modality: RT alone, Chemo? : none, Dose: 70.0, Fx: 35, Local: none, Regional: none, Distant: none, 2nd Ca: none, ContrastEnhanced: 1\nAnswer: ",
        "recruit-recruiter": "1. Radiation Oncologist - Your expertise is strictly limited to radiation therapy planning and dosing for head and neck squamous cell carcinoma, especially HPV-negative cases involving the larynx. - Hierarchy: Radiation Oncologist",
        "initial_assessment-radiation oncologist": "Step-by-step analysis as a radiation oncologist:\n\n1. The CT scan is of the head and neck region, with two bounding boxes provided:\n   - Box 1: [262, 219, 125, 262, 251, 155]\n   - Box 2: [253, 172, 76, 253, 190, 87]\n\n2. These coordinates are normalized and define volumetric regions within the scan. The first box appears to be located more posteriorly and inferiorly, possibly encompassing part of the oropharynx or hypopharynx region, or adjacent soft tissues. The second box is more anterior and superior, possibly involving structures like the base of tongue or oropharyngeal mucosa.\n\n3. From a radiation oncology perspective, these ROIs could represent either tumor volumes or involved lymph nodes. The presence of multiple ROIs suggests multifocal disease or primary tumor plus nodal involvement.\n\n4. Without direct visualization of the scan, but given the anatomical location, these regions could correspond to squamous cell carcinoma sites in the oropharynx or hypopharynx, common sites for HPV-related or HPV-negative head and neck cancers.\n\n5. Important considerations for survival probability include:\n   - Tumor site and subsite (oropharynx/hypopharynx)\n   - HPV status (not provided here)\n   - Tumor and nodal staging (not provided)\n   - Patient factors (age, performance status, smoking history)\n   - Treatment modality and dose\n\n6. Since the question only provides bounding boxes and no clinical or pathological data, the survival probability cannot be precisely estimated. However, from a radiation oncologist's perspective, involvement of multiple regions in the oropharynx/hypopharynx with possible nodal disease generally indicates at least stage III or higher disease, which may reduce survival probability compared to early-stage disease.\n\n7. If these ROIs represent gross tumor volumes (GTV) and involved nodes, definitive radiation therapy with or without chemotherapy would be indicated, with typical doses around 70 Gy to gross disease.\n\nFinal answer:  \nAnswer:Dead",
        "initial_assessment_review_assessment-radiation oncologist": "Answer:Alive",
        "Round 1-role-comment": "radiation oncologist:alive",
        "Round 1-num_agents": 1,
        "Round 2-Turn 1-discuss-participate_review_assessment-radiation oncologist": "Answer:no",
        "Round 2-Turn 1-ask_gap_review_assessment-radiation oncologist": "---\nAnswer: no\nReason: Current expertise covers required scope\n---",
        "Round 2-role-comment": "radiation oncologist:alive",
        "Round 2-num_agents": 1,
        "num_cooperations-panel": 0,
        "decision-Moderator": "('Answer: Alive',)"
    }
}